Indian Journal of Clinical and Experimental Ophthalmology

Print ISSN: 2395-1443

Online ISSN: 2395-1451

CODEN : IJCEKF

Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...

Article type

Editorial


Article page

317- 319


Authors Details

Farzad Pakdel*


Article Metrics


View Article As

 


Downlaod Files

   






Article statistics

Viewed: 497

PDF Downloaded: 303


Very early endoscopic DCR in acute suppurative dacryocystitis perspective


Editorial

Author Details : Farzad Pakdel*

Volume : 8, Issue : 3, Year : 2022

Article Page : 317-319

https://doi.org/10.18231/j.ijceo.2022.065



Suggest article by email

Get Permission

Abstract

Acute dacryocystitis is not uncommon in oculofacial and general ophthalmology clinics admissions. It happens with sudden inflammation of lacrimal sac that frequently occurs in the setting of pre-existing nasolacrimal duct obstruction. Long standing tear flow stasis results in change of bacterial flora and bacterial over-growth in the lacrimal sac as a reservoir of stagnant tear., However, acute dacryocystitis can be associated with dacryoliths or indefinite pre-existing anatomic nasolacrimal duct obstruction.
 


How to cite : Pakdel F, Very early endoscopic DCR in acute suppurative dacryocystitis perspective. Indian J Clin Exp Ophthalmol 2022;8(3):317-319

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.